Abstract
The etiopathogenesis of chronic spontaneous urticaria (CSU) is not fully elucidated, and almost 30–40% of patients are resistant to treatments; therefore, there is still a need for the development of new and effective treatments. This study aimed to develop experimental cellular therapy for CSU patients resistant to current treatment options. Autologous adipose tissue mesenchymal stem cells (MSC) were administered to 10 refractory CSU patients who were then followed up for six months. The efficacy of treatment was evaluated according to the weekly urticaria activity scores (UAS7) and drug use scores (DUS7). To observe the effect of treatment on immune cells, CD4+ T cell subsets were analyzed by flow cytometry, and the serum IFN-γ, TNF-α, IL2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17a, IL-21, IL-22, TGF-β1, PGE2, IDO and anti-FcεRI levels were measured using the Luminex and ELISA methods. The values obtained were compared with 10 control refractory CSU patients and five healthy controls. We found that the T cell subsets and inflammatory molecules were not affected by MSC treatment during the follow-up period. In control patients, a significant decrease was detected only at the Th2 subset, TGF-β1, PGE2, IDO and anti-FcεRI levels on the 14th day of treatment. The UAS7 and DUS7 values of the MSC-treated patients significantly decreased during the follow-up period, but in control patients, a significant but temporary decrease was seen. According to our findings, unlike conventional treatment, MSC therapy resulted in longer and more effective recovery. Our data indicate that MSCs may be an alternative and effective approach for treatment-resistant CSU patients.
Similar content being viewed by others
Abbreviations
- AHs:
-
Antihistamines
- ANA:
-
Anti-nuclear antibody
- Anti-TG:
-
Anti-thyroglobulin
- Anti-TPO:
-
Anti-thyroid peroxidase
- ASST:
-
Autologous serum skin test
- BC:
-
Basophile cell
- CSU:
-
Chronic spontaneous urticaria
- DUS7:
-
Weekly drug use scores
- EAACI:
-
The European Academy of Allergy and Clinical Immunology
- EDF:
-
European Dermatology Forum
- FcεRI:
-
High-affinity receptor for IgE
- GA2LEN:
-
Global Allergy and Asthma European Network
- IDO:
-
Indoleamine 2,3-dioxygenase
- IFN-γ:
-
Interferon gamma
- Ig:
-
Immunoglobulin
- IL:
-
Interleukin
- MC:
-
Mast cell
- MSC:
-
Mesenchymal stem cell
- PGE2:
-
Prostaglandin E2
- TGF-β1:
-
Transforming growth factor beta 1
- TNF-α:
-
Tumor necrosis factor alpha
- Treg:
-
Regulatory T cell
- UAS7:
-
Weekly urticaria activity scores
- WAO:
-
World Allergy Organization
References
Nam, Y.-H., Kim, J.-H., Jin, H. J., Hwang, E.-K., Shin, Y.-S., Ye, Y.-M., & Park, H.-S. (2012). Effects of Omalizumab treatment in patients with refractory chronic Urticaria. Allergy, Asthma & Immunology Research, 4(6), 357–361. https://doi.org/10.4168/aair.2012.4.6.357.
Maurer, M., Eyerich, K., Eyerich, S., Ferrer, M., Gutermuth, J., Hartmann, K., Jakob, T., Kapp, A., Kolkhir, P., Larenas-Linnemann, D., Park, H. S., Pejler, G., Sánchez-Borges, M., Schäkel, K., Simon, D., Simon, H. U., Weller, K., Zuberbier, T., & Metz, M. (2020). Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. International Archives of Allergy and Immunology, 181(5), 321–333. https://doi.org/10.1159/000507218.
Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A. H., Baker, D., Ballmer-Weber, B., … Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA2LEN, IAACI, IADVL, JDA, NVvA, MSAI, ÖGDV, PSA, RAACI, SBD, SFD, SGAI, SGDV, SIAAIC, SIDeMaST, SPDV, TSD, UNBB, UNEV and WAO. (2018). The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy, 73(7), 1393–1414. https://doi.org/10.1111/all.13397
Zuberbier, T., Asero, R., Bindslev-Jensen, C., Canonica, G. W., Church, M. K., Giménez-Arnau, A. M., et al. (2009). EAACI/GA2LEN/EDF/WAO guideline: Management of urticaria. Allergy, 64(10), 1427–1443. https://doi.org/10.1111/j.1398-9995.2009.02178.x.
Grattan, C. E., Wallington, T. B., Warin, R. P., Kennedy, C. T., & Bradfield, J. W. (1986). A serological mediator in chronic idiopathic urticaria--a clinical, immunological and histological evaluation. The British Journal of Dermatology, 114(5), 583–590.
Leznoff, A., Josse, R. G., Denburg, J., & Dolovich, J. (1983). Association of chronic urticaria and angioedema with thyroid autoimmunity. Archives of Dermatology, 119(8), 636–640.
Bracken, S. J., Abraham, S., & MacLeod, A. S. (2019). Autoimmune theories of chronic spontaneous Urticaria. Frontiers in Immunology, 10. https://doi.org/10.3389/fimmu.2019.00627.
Salman, A., Demir, G., & Bekiroglu, N. (2019). The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data. Dermatologic Therapy, e12975. https://doi.org/10.1111/dth.12975.
Magerl, M., Philipp, S., Manasterski, M., Friedrich, M., & Maurer, M. (2007). Successful treatment of delayed pressure urticaria with anti-TNF-alpha. The Journal of Allergy and Clinical Immunology, 119(3), 752–754. https://doi.org/10.1016/j.jaci.2006.12.658.
O’Donnell, B. F., Barr, R. M., Black, A. K., Francis, D. M., Kermani, F., Niimi, N., et al. (1998). Intravenous immunoglobulin in autoimmune chronic urticaria. The British Journal of Dermatology, 138(1), 101–106.
Ue, A. P. F. de, Souza, P. K. de, Rotta, O., Furlani, W. de J., Lima, A. R. M. de, & Sabbag, D. S. O. V. (2011). Quality of life assessment in patients with chronic urticaria. Anais Brasileiros de Dermatologia, 86(5), 879–904. https://doi.org/10.1590/S0365-05962011000500006.
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., … Horwitz, E. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8(4), 315–317. https://doi.org/10.1080/14653240600855905.
Ankrum, J. A., Ong, J. F., & Karp, J. M. (2014). Mesenchymal stem cells: immune evasive, not immune privileged. Nature Biotechnology, 32(3), 252–260. https://doi.org/10.1038/nbt.2816.
Tyndall, A. (2012). Application of autologous stem cell transplantation in various adult and pediatric rheumatic diseases. Pediatric Research, 71(4–2), 433–438. https://doi.org/10.1038/pr.2011.66.
Raphael, I., Nalawade, S., Eagar, T. N., & Forsthuber, T. G. (2015). T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine, 74(1), 5–17. https://doi.org/10.1016/j.cyto.2014.09.011.
Dardalhon, V., Korn, T., Kuchroo, V. K., & Anderson, A. C. (2008). Role of Th1 and Th17 cells in organ-specific autoimmunity. Journal of Autoimmunity, 31(3), 252–256. https://doi.org/10.1016/j.jaut.2008.04.017.
Lee, G. R. (2018). The balance of Th17 versus Treg cells in autoimmunity. International Journal of Molecular Sciences, 19(3). https://doi.org/10.3390/ijms19030730.
El, N. (2011). Mesenchymal stem cells: Immunology and therapeutic benefits. In A. Gholamrezanezhad (Ed.), Stem cells in clinic and research. InTech. Retrieved from http://www.intechopen.com/books/stem-cells-in-clinic-and-research/mesenchymal-stem-cells-immunology-and-therapeutic-benefits
Özdemir, A. T., Özgül Özdemir, R. B., Kırmaz, C., Sarıboyacı, A. E., Ünal Halbutoğlları, Z. S., Özel, C., & Karaöz, E. (2016). The paracrine immunomodulatory interactions between the human dental pulp derived mesenchymal stem cells and CD4 T cell subsets. Cellular Immunology, 310, 108–115. https://doi.org/10.1016/j.cellimm.2016.08.008.
Yan, Z., Zhuansun, Y., Chen, R., Li, J., & Ran, P. (2014). Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism. Experimental Cell Research, 324(1), 65–74. https://doi.org/10.1016/j.yexcr.2014.03.013.
Cagliani, J., Grande, D., Molmenti, E. P., Miller, E. J., & Rilo, H. L. R. (2017). Immunomodulation by Mesenchymal stromal cells and their clinical applications. Journal of Stem Cell and Regenerative Biology, 3(2). https://doi.org/10.15436/2471-0598.17.022.
Search of: mesenchymal stem cell | Graft Vs Host Disease - Search Details - ClinicalTrials.gov. (n.d.). Retrieved September 15, 2020, from https://clinicaltrials.gov/ct2/results/details?term=mesenchymal+stem+cell&cond=Graft+Vs+Host+Disease
Search of: mesenchymal stem cell | Autoimmune Diseases - Search Details - ClinicalTrials.gov. (n.d.). Retrieved September 15, 2020, from https://clinicaltrials.gov/ct2/results/details?term=mesenchymal+stem+cell&cond=Autoimmune+Diseases
Gao, F., Chiu, S. M., Motan, D. a. L., Zhang, Z., Chen, L., Ji, H.-L., … Lian, Q. (2016). Mesenchymal stem cells and immunomodulation: Current status and future prospects. Cell Death & Disease, 7(1), e2062. https://doi.org/10.1038/cddis.2015.327.
Wang, L.-T., Ting, C.-H., Yen, M.-L., Liu, K.-J., Sytwu, H.-K., Wu, K. K., & Yen, B. L. (2016). Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: Review of current clinical trials. Journal of Biomedical Science, 23(1), 76. https://doi.org/10.1186/s12929-016-0289-5.
Bernstein, J. A., Lang, D. M., Khan, D. A., Craig, T., Dreyfus, D., Hsieh, F., Sheikh, J., Weldon, D., Zuraw, B., Bernstein, D. I., Blessing-Moore, J., Cox, L., Nicklas, R. A., Oppenheimer, J., Portnoy, J. M., Randolph, C. R., Schuller, D. E., Spector, S. L., Tilles, S. A., & Wallace, D. (2014). The diagnosis and management of acute and chronic urticaria: 2014 update. Journal of Allergy and Clinical Immunology, 133(5), 1270–1277. https://doi.org/10.1016/j.jaci.2014.02.036.
Gn, K., R, A., M, M., Ra, S., P, S.-G., & Ce, G. (2009, September). EAACI/GA(2)LEN task force consensus report: The autologous serum skin test in urticaria. Allergy. Allergy. https://doi.org/10.1111/j.1398-9995.2009.02132.x
Kaplan, A., Ferrer, M., Bernstein, J. A., Antonova, E., Trzaskoma, B., Raimundo, K., Rosén, K., Omachi, T. A., Khalil, S., & Zazzali, J. L. (2016). Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. The Journal of Allergy and Clinical Immunology, 137(2), 474–481. https://doi.org/10.1016/j.jaci.2015.08.023.
Lee, M.-F., Lin, T.-M., Liu, S.-W., & Chen, Y.-H. (2014). A rapid method of detecting autoantibody against FcεRIα for chronic spontaneous Urticaria. PLoS One, 9(10), e109565. https://doi.org/10.1371/journal.pone.0109565.
Ertas, R., Ozyurt, K., Atasoy, M., Hawro, T., & Maurer, M. (2018). The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy, 73(3), 705–712. https://doi.org/10.1111/all.13345.
De Swerdt, A., Van Den Keybus, C., Kasran, A., Cadot, P., Neyens, K., Coorevits, L., et al. (2005). Detection of basophil-activating IgG autoantibodies in chronic idiopathic urticaria by induction of CD63. Journal of Allergy and Clinical Immunology, 116(3), 662–667. https://doi.org/10.1016/j.jaci.2005.04.042.
Chen, W., Si, S., Wang, X., Liu, J., Xu, B., Yin, M., … Liu, J. (2016). The profiles of T lymphocytes and subsets in peripheral blood of patients with chronic idiopathic urticaria., 9(7), 7428–7435.
Irinyi, B., Aleksza, M., Antal-Szalmás, P., Sipka, S., Hunyadi, J., & Szegedi, A. (2002). Cytokine production of CD4+ and CD8+ peripheral T lymphocytes in patients with chronic idiopathic urticaria. Acta Dermato-Venereologica, 82(4), 249–253. https://doi.org/10.1080/000155502320323199.
Lopes, A., Machado, D., Pedreiro, S., Henriques, A., Silva, I., Tavares, B., Inácio, M. J., Chieira, C., Martinho, A., Pais, M. L., Pereira, C., & Paiva, A. (2013). Different frequencies of Tc17/Tc1 and Th17/Th1 cells in chronic spontaneous urticaria. International Archives of Allergy and Immunology, 161(2), 155–162. https://doi.org/10.1159/000345401.
Cosmi, L., Maggi, L., Santarlasci, V., Liotta, F., & Annunziato, F. (2014). T helper cells plasticity in inflammation. Cytometry Part A, 85(1), 36–42. https://doi.org/10.1002/cyto.a.22348.
Chen, W.-C., Chiang, B.-L., Liu, H. E., Leu, S.-J., & Lee, Y.-L. (2008). Defective functions of circulating CD4+CD25+ and CD4+CD25- T cells in patients with chronic ordinary urticaria. Journal of Dermatological Science, 51(2), 121–130. https://doi.org/10.1016/j.jdermsci.2008.02.012.
Arshi, S., Babaie, D., Nabavi, M., Tebianian, M., Ghalehbaghi, B., Jalali, F., Ahmadvand, A., & Gholami, R. (2014). Circulating level of CD4+ CD25+ FOXP3+ T cells in patients with chronic urticaria. International Journal of Dermatology, 53(12), e561–e566. https://doi.org/10.1111/ijd.12630.
Ullah, M., Liu, D. D., & Thakor, A. S. (2019). Mesenchymal stromal cell homing: Mechanisms and strategies for improvement. iScience, 15, 421–438. https://doi.org/10.1016/j.isci.2019.05.004.
Alasandagutti, M. L., Ponnana, M., Sivangala, R., Thada, S., Joshi, L., Hussain, H., Ansari, S. S., Valluri, V., & Gaddam, S. L. (2014). Role of IFN-γ and IL-6 cytokines and their association in determining susceptibility to chronic idiopathic urticaria. Genetic Testing and Molecular Biomarkers, 18(12), 804–809. https://doi.org/10.1089/gtmb.2014.0193.
Chen, Q., Zhong, H., Chen, W. C., Zhai, Z., Zhou, Z., Song, Z., & Hao, F. (2018). Different expression patterns of plasma Th1-, Th2-, Th17- and Th22-related cytokines correlate with serum autoreactivity and allergen sensitivity in chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology: JEADV, 32(3), 441–448. https://doi.org/10.1111/jdv.14541.
de Petrola, M. R. C., Quintero, V., Ruiz, N. B., Flores, M. E., & Pacheco, M. (2009). Serum Th1 and Th2 cytokines in chronic Urticaria patients. Journal of Allergy and Clinical Immunology, 123(2), S105. https://doi.org/10.1016/j.jaci.2008.12.382.
Liao, W., Lin, J.-X., & Leonard, W. J. (2011). IL-2 family cytokines: New insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Current Opinion in Immunology, 23(5), 598–604. https://doi.org/10.1016/j.coi.2011.08.003.
Mitra, S., & Leonard, W. J. (2018). Biology of IL-2 and its therapeutic modulation: Mechanisms and strategies. Journal of Leukocyte Biology, 103(4), 643–655. https://doi.org/10.1002/JLB.2RI0717-278R.
Schoenborn, J. R., & Wilson, C. B. (2007). Regulation of interferon-gamma during innate and adaptive immune responses. Advances in Immunology, 96, 41–101. https://doi.org/10.1016/S0065-2776(07)96002-2.
Wynn, T. A. (2003). IL-13 effector functions. Annual Review of Immunology, 21, 425–456. https://doi.org/10.1146/annurev.immunol.21.120601.141142.
Bae, Y., Izuhara, K., Ohta, S., Ono, J., Hong, G. U., Ro, J. Y., Park, G. H., & Choi, J. H. (2016). Periostin and Interleukin-13 are independently related to chronic spontaneous Urticaria. Allergy, Asthma & Immunology Research, 8(5), 457–460. https://doi.org/10.4168/aair.2016.8.5.457.
Caproni, M., Cardinali, C., Giomi, B., Antiga, E., D’Agata, A., Walter, S., & Fabbri, P. (2004). Serological detection of eotaxin, IL-4, IL-13, IFN-gamma, MIP-1alpha, TARC and IP-10 in chronic autoimmune urticaria and chronic idiopathic urticaria. Journal of Dermatological Science, 36(1), 57–59. https://doi.org/10.1016/j.jdermsci.2004.07.006.
McLeod, J. J. A., Baker, B. N., & Ryan, J. J. (2015). Mast cell production and response to IL-4 and IL-13. Cytokine, 75(1), 57–61. https://doi.org/10.1016/j.cyto.2015.05.019.
Beck, L. A., Marcotte, G. V., MacGlashan, D., Togias, A., & Saini, S. (2004). Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. The Journal of Allergy and Clinical Immunology, 114(3), 527–530. https://doi.org/10.1016/j.jaci.2004.06.032.
Prendergast, G. C., Metz, R., Muller, A. J., Merlo, L. M. F., & Mandik-Nayak, L. (2014). IDO2 in immunomodulation and autoimmune disease. Frontiers in Immunology, 5. https://doi.org/10.3389/fimmu.2014.00585.
Saxena, V., Lienesch, D. W., Zhou, M., Bommireddy, R., Azhar, M., Doetschman, T., & Singh, R. R. (2008). Dual roles of Immunoregulatory cytokine TGF-β in the pathogenesis of autoimmunity-mediated organ damage. Journal of immunology (Baltimore, Md. : 1950), 180(3), 1903–1912.
Tsuge, K., Inazumi, T., Shimamoto, A., & Sugimoto, Y. (2019). Molecular mechanisms underlying prostaglandin E2-exacerbated inflammation and immune diseases. International Immunology, 31(9), 597–606. https://doi.org/10.1093/intimm/dxz021.
Bax, H. J., Keeble, A. H., & Gould, H. J. (2012). Cytokinergic IgE action in mast cell activation. Frontiers in Immunology, 3, 229. https://doi.org/10.3389/fimmu.2012.00229.
Acknowledgements
We thank Dr. Yusuf Metin Gelmez and Mr. Abdullah Yılmaz from Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Immunology for their valuable help in flow cytometry analyses.
Funding
The Scientific and Technological Research Council of Turkey (TUBITAK) financially supported this study with reference number 215 S 612.
Author information
Authors and Affiliations
Contributions
RBÖÖ: Conceptualization, Methodology, Investigation, Resources, Data Curation, Writing - Original Draft, ATÖ: Conceptualization, Methodology, Formal analysis, Investigation, Visualization, Data Curation, Writing - Original Draft, CK: Conceptualization, Methodology, Resources, Supervision, Project administration, Funding acquisition, Writing - Review & Editing, EO: Methodology, Investigation, Supervision, Writing - Review & Editing, EÖ: Methodology, Formal analysis, Supervision, Writing - Review & Editing, HK: Methodology, Resources, Writing - Review & Editing, MKE: Methodology, Resources, Writing - Review & Editing, GD: Methodology, Formal analysis, Supervision, Writing - Review & Editing.
Corresponding author
Ethics declarations
Conflict of Interest
Prof. Ercüment Ovalı is an employee of Acıbadem Labcell, Istanbul. The other authors declared no potential conflict of interest with respect to the research, authorship, and/or publication of this article.
Clinical Trial Registration
The presented study was registered at the U.S. National Library of Medicine clinicaltrials.gov website (Registration no: NCT02824393 and URL. https://clinicaltrials.gov/ct2/show/NCT02824393).
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 25 kb)
Rights and permissions
About this article
Cite this article
Özgül Özdemir, R.B., Özdemir, A.T., Kırmaz, C. et al. Mesenchymal Stem Cells: a Potential Treatment Approach for Refractory Chronic Spontaneous Urticaria. Stem Cell Rev and Rep 17, 911–922 (2021). https://doi.org/10.1007/s12015-020-10059-w
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12015-020-10059-w